Neoadjuvant WX-0593 in Resectable ALK-positive or ROS1-positive Non-small Cell Lung Cancer
NCT05765877
·
clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
26
Enrollment
OTHER
Sponsor class
Conditions
Non-Small Cell Lung Cancer(NSCLC)
Interventions
DRUG:
WX-0593 Tablets
Sponsor
Pingping Song